Dasatinib monohydrate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 100230

CAS#: 863127-77-9 (hydrate)

Description: Dasatinib, also known as BMS-354825, is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations.


Price and Availability

Size
Price

500mg
USD 70
5g
USD 190
50g
USD 1250
500g
USD 4950
Size
Price

1g
USD 80
10g
USD 290
100g
USD 2250
1kg
Ask price
Size
Price

2g
USD 110
20g
USD 650
200g
USD 3450

Dasatinib hydrate, purity > 99%, is in stock. The same day shipping out after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 100230
Name: Dasatinib monohydrate
CAS#: 863127-77-9 (hydrate)
Chemical Formula: C22H28ClN7O3S
Exact Mass: 487.15572
Molecular Weight: 506.02
Elemental Analysis: C, 52.22; H, 5.58; Cl, 7.01; N, 19.38; O, 9.49; S, 6.34


Synonym: BMS354825; BMS-354825; BMS354825. Dasatinib; US brand name: Sprycel.

IUPAC/Chemical Name: N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide monohydrate.

InChi Key: XHXFZZNHDVTMLI-UHFFFAOYSA-N

InChi Code: InChI=1S/C22H26ClN7O2S.H2O/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31;/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27);1H2

SMILES Code: O=C(C1=CN=C(NC2=NC(C)=NC(N3CCN(CCO)CC3)=C2)S1)NC4=C(C)C=CC=C4Cl.[H]O[H]


Technical Data

Appearance:
white solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

Related CAS#
863127-77-9 (Dasatinib monohydrate);
302962-49-8 (Dasatinib).


References

1: Korashy HM, Rahman AF, Kassem MG. Dasatinib. Profiles Drug Subst Excip Relat Methodol. 2014;39:205-37. doi: 10.1016/B978-0-12-800173-8.00004-0. Review. PubMed PMID: 24794907.

2: Lindauer M, Hochhaus A. Dasatinib. Recent Results Cancer Res. 2014;201:27-65. doi: 10.1007/978-3-642-54490-3_2. Review. PubMed PMID: 24756784.

3: Qiu ZY, Xu W, Li JY. Large granular lymphocytosis during dasatinib therapy. Cancer Biol Ther. 2014 Mar 1;15(3):247-55. doi: 10.4161/cbt.27310. Epub 2013 Dec 18. Review. PubMed PMID: 24352048; PubMed Central PMCID: PMC3974824.

4: Nagao T, Takahashi N, Kameoka Y, Noguchi S, Shinohara Y, Ohyagi H, Kume M, Sawada K. Dasatinib-responsive chronic lymphocytic leukemia in a patient treated for coexisting chronic myeloid leukemia. Intern Med. 2013;52(22):2567-71. Review. PubMed PMID: 24240798.

5: Paydas S. Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect? Crit Rev Oncol Hematol. 2014 Feb;89(2):242-7. doi: 10.1016/j.critrevonc.2013.10.005. Epub 2013 Oct 12. Review. PubMed PMID: 24210599.

6: Signorovitch J, Ayyagari R, Reichmann WM, Wu EQ, Chen L. Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis. Cancer Treat Rev. 2014 Mar;40(2):285-92. doi: 10.1016/j.ctrv.2013.09.004. Epub 2013 Sep 17. Review. PubMed PMID: 24112812.

7: Eadie LN, Hughes TP, White DL. Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib. Clin Pharmacol Ther. 2014 Mar;95(3):294-306. doi: 10.1038/clpt.2013.208. Epub 2013 Oct 9. Review. PubMed PMID: 24107928.

8: Hochhaus A, Kantarjian H. The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients. J Cancer Res Clin Oncol. 2013 Dec;139(12):1971-84. doi: 10.1007/s00432-013-1488-z. Epub 2013 Aug 13. Review. PubMed PMID: 23942795; PubMed Central PMCID: PMC3825579.

9: Brazzelli V, Grasso V, Borroni G. Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience. J Eur Acad Dermatol Venereol. 2013 Dec;27(12):1471-80. doi: 10.1111/jdv.12172. Epub 2013 Apr 24. Review. PubMed PMID: 23611501.

10: Keating GM, Lyseng-Williamson KA, McCormack PL, Keam SJ. Dasatinib: a guide to its use in chronic myeloid leukemia in the EU. BioDrugs. 2013 Jun;27(3):275-9. doi: 10.1007/s40259-013-0024-7. Review. PubMed PMID: 23549840.